查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1971068

催产素市场－全球产业规模、份额、趋势、机会、预测：按适应症、通路、地区和竞争格局划分，2021-2031年

Oxytocin Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Antepartum, Postpartum), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球催产素市场预计将从 2025 年的 15.5 亿美元成长到 2031 年的 23.1 亿美元，复合年增长率为 6.91%。

催产素是一种强效的子宫收缩胜肽激素，主要用于透过促进子宫收缩来引产和控制产后出血。市场成长主要受妊娠併发症日益增多以及医疗机构广泛实施积极的第三产程管理通讯协定的推动。此外，全球剖腹产数量的增加使得定期预防性使用该药物以减少术中出血成为必要，从而导致已开发市场和新兴市场对合成製剂和非专利的需求持续增长。市场持续发展面临的一大障碍是药品供应链的脆弱性。这导致无菌注射剂频繁且严重短缺，造成采购瓶颈。这种不稳定性使得製造商无法有效地满足全球需求并实现收入目标。据美国医疗保健系统药剂师协会称，2024年第一季医疗保健产业出现了创纪录的323种药品短缺，严重影响了催产素等基本急救药物的供应。这些物流方面的限制，加上严格的低温运输储存要求，仍然是市场持续扩张的主要障碍。

市场概览
预测期 2027-2031
市场规模：2025年 15.5亿美元
市场规模：2031年 23.1亿美元
复合年增长率：2026-2031年 6.91%
成长最快的细分市场 产后
最大的市场 北美洲

市场驱动因素

产后出血（PPH）发生率的上升是催产素市场的重要驱动因素，常规使用促进子宫收缩的药物已成为标准治疗方法。由于产后出血仍然是全球孕产妇死亡的主要原因之一，医疗卫生系统正在积极实施主动管理通讯协定，要求在分娩第三产程预防性使用催产素。这种临床需求正在推动催产素的大规模采购，尤其是在分娩风险较高的地区，预防过度出血是首要任务。根据联合国人口基金2024年母婴健康基金年度影响报告，到2025年7月，将有超过600万名孕妇透过该基金的服务获得安全分娩护理，这凸显了保护孕产妇健康所需药物的巨大规模。同时，耐热性和新型製剂的进步正在从根本上扩大市场覆盖范围，克服了资源匮乏地区低温运输的障碍。这些创新确保了产品即使在电力供应不稳定的热带气候下也能有效发挥作用，开闢了新的通路，并减少了废弃物。费林製药在2024年永续发展报告中指出，2024年将向中低收入国家供应150万剂耐热Carbetocin缩宫素，较去年同期成长50%。此外，现有学名药生产商也在提高产能以满足不断增长的需求。希克玛製药的全球注射剂业务在2024年实现了9%的收入成长，达到13亿美元。这反映了包括催产素在内的基本无菌药物的强劲需求。

市场挑战

无菌注射剂药品供应链的脆弱性是全球催产素市场成长的主要障碍。这种脆弱性源于无菌肽激素，其中对无菌性和稳定性的严格品管至关重要。全球数量有限的生产设施一旦出现生产线故障或监管合规问题，就会即时造成供应瓶颈。这种中断阻碍了製造商利用日益增长的子宫收缩药物临床需求，直接导致商机的损失和已开发地区及新兴市场扩张的停滞。因此，医疗保健机构经常面临这种关键急性治疗药物供应不稳定的问题，导致市场停滞。美国系统药剂师协会 (ASHP) 报告称，2024 年将出现 95 种新的药品短缺，其中约 50% 与注射剂相关。供应中断的频繁发生，尤其是在註射剂领域，凸显了催产素市场面临的严峻物流风险。除非确保可靠的库存水平，否则将无法持续满足剖腹产率上升和产后出血处理通讯协定实施后带来的不断增长的需求，从而有效地限制市场价值的潜在上限。

市场趋势

随着临床研究拓展至神经精神疾病和行为障碍领域，这种荷尔蒙的效用正超越其传统的产科应用。药厂正积极研发鼻腔製剂，以应对普拉德-威利症候群和泛自闭症障碍等复杂疾病。这一趋势代表着一项策略性倡议，旨在利用该激素调节与饱腹感和社交联繫相关的神经通路的能力。据Tonix Pharmaceuticals公司称，其用于治疗普拉德-儿童症候群（一种影响美国不到20万人的遗传性疾病）的强化催产素疗法TNX-2900于2024年3月获得美国食品药品监督管理局（FDA）授予的罕见儿童疾病适应症资格。同时，随着医疗保健系统寻求更安全的鸦片类药物危机解决方案，催产素作为非鸦片类镇痛替代疗法的研究正在加速推进。研究机构正在评估催产素的止痛特性，尤其着眼于降低老化社会和慢性疼痛患者的鸦片类药物成瘾。这项临床研究旨在检验催产素作为辅助性治疗能否降低鸦片类药物的剂量需求并减轻药物依赖风险。据佛罗里达大学称，研究人员于2024年9月获得美国国立卫生研究院（NIH）414,375美元的津贴，用于开展一项临床试验，评估合成催产素在减少老年人阿片类药物使用方面的有效性。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球催产素市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 适应症（产前、产后）
    • 分销通路（医院药局、零售药局、网路药局）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美催产素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲催产素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区催产素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲催产素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲催产素市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球催产素市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Bimeda Group
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Grindeks
  • Pfizer, Inc.
  • Weefsel Pharma
  • EVER Pharma
  • AdvaCare Pharma
  • Fresenius Kabi AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23826

The Global Oxytocin Market is projected to expand from USD 1.55 Billion in 2025 to USD 2.31 Billion by 2031, reflecting a CAGR of 6.91%. As a potent uterotonic peptide hormone, oxytocin is primarily administered to induce labor and manage postpartum hemorrhage by stimulating uterine contractions. The market is largely driven by the increasing prevalence of pregnancy-related complications and the universal implementation of Active Management of the Third Stage of Labor protocols across medical institutions. Additionally, the rising number of cesarean section deliveries worldwide necessitates the routine prophylactic use of this medication to minimize surgical blood loss, ensuring sustained demand for both synthetic and generic formulations in developed and emerging economies. A significant obstacle to market continuity is the fragility of the pharmaceutical supply chain, which frequently leads to critical inventory shortages of sterile injectables. This instability results in procurement bottlenecks that hinder manufacturers from efficiently meeting global requirements and achieving revenue targets. According to the American Society of Health-System Pharmacists, the healthcare sector faced a record 323 active drug shortages in the first quarter of 2024, a crisis that severely impacts the availability of essential acute care medications like oxytocin. These logistical constraints, exacerbated by strict cold-chain storage requirements, remain a primary barrier to consistent market expansion.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.55 Billion
Market Size 2031USD 2.31 Billion
CAGR 2026-20316.91%
Fastest Growing SegmentPostpartum
Largest MarketNorth America

Market Driver

The rising incidence of Postpartum Hemorrhage (PPH) serves as a critical driver for the oxytocin market, necessitating the routine administration of uterotonics as a standard of care. Since PPH remains the leading cause of maternal mortality globally, healthcare systems are aggressively adopting active management protocols that mandate prophylactic oxytocin use during the third stage of labor. This clinical necessity fuels high-volume procurement, particularly in regions with elevated obstetric risks where preventing excessive blood loss is paramount. The United Nations Population Fund's 'Maternal and Newborn Health Fund Annual Impact Report 2024' noted that more than 6 million pregnant women accessed safer delivery care through their services in July 2025, highlighting the immense scale of medication required to safeguard maternal health. Simultaneously, advancements in heat-stable and novel formulations are fundamentally expanding market reach by overcoming cold-chain logistical barriers in low-resource settings. These innovations ensure product efficacy in tropical climates with unreliable electricity access, thereby opening new distribution channels and reducing wastage. Ferring Pharmaceuticals reported in its 'Sustainability Report 2024' that it supplied 1.5 million doses of heat-stable Carbetocin Ferring to lower-middle-income countries in 2024, a 50% increase from the previous year. Furthermore, established generic manufacturers are strengthening production capabilities to meet this growing need; Hikma Pharmaceuticals' global Injectables business achieved a 9% revenue increase to $1.3 billion in 2024, reflecting resilient demand for essential sterile medications including oxytocin.

Market Challenge

The fragility of the pharmaceutical supply chain for sterile injectables acts as a primary impediment to the growth of the global oxytocin market. This vulnerability stems from the complexity of manufacturing sterile peptide hormones, where strict quality control regarding sterility and stability is non-negotiable. When manufacturing lines fail or regulatory compliance issues arise at the limited number of global production facilities, immediate procurement bottlenecks occur. These disruptions prevent manufacturers from capitalizing on the rising clinical demand for uterotonics, directly causing lost revenue opportunities and stalling market expansion in both developed and emerging regions. Consequently, healthcare providers often face inconsistent availability of this critical acute care medication, forcing market stagnation. The American Society of Health-System Pharmacists identified 95 new drug shortages in 2024, with nearly 50% involving injectable medications. This high prevalence of supply failures specifically within the injectable category underscores the severe logistical risks facing the oxytocin market. Without reliable inventory levels, the market cannot sustain the volume growth required by the increasing rates of cesarean sections and postpartum hemorrhage protocols, effectively capping potential valuation.

Market Trends

The Expansion of Clinical Research into Neuropsychiatric and Behavioral Disorders is extending the hormone's utility beyond traditional obstetrics. Pharmaceutical developers are aggressively investigating intranasal formulations to address complex conditions like Prader-Willi syndrome and autism spectrum disorder. This trend highlights a strategic move to capitalize on the hormone's ability to modulate neural pathways associated with satiety and social bonding. According to Tonix Pharmaceuticals, in March 2024, the company received Rare Pediatric Disease Designation from the FDA for TNX-2900, a potentiated oxytocin therapy for Prader-Willi syndrome, a genetic disorder affecting fewer than 200,000 people in the United States. Concurrently, the Investigation of Oxytocin as a Non-Opioid Alternative for Pain Management is accelerating as healthcare systems seek safer solutions to the opioid crisis. Research institutions are evaluating the analgesic properties of oxytocin specifically to reduce opioid dependence in aging populations and patients with chronic pain. This clinical focus aims to validate oxytocin as an adjunctive therapy that can lower required opioid dosages and mitigate addiction risks. According to the University of Florida, researchers secured a $414,375 grant from the National Institutes of Health in September 2024 to conduct a clinical trial assessing synthetic oxytocin's efficacy in curbing opioid use among older adults.

Key Market Players

  • Bimeda Group
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Grindeks
  • Pfizer, Inc.
  • Weefsel Pharma
  • EVER Pharma
  • AdvaCare Pharma
  • Fresenius Kabi AG

Report Scope

In this report, the Global Oxytocin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oxytocin Market, By Indication

  • Antepartum
  • Postpartum

Oxytocin Market, By Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Oxytocin Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oxytocin Market.

Available Customizations:

Global Oxytocin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oxytocin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Antepartum, Postpartum)
    • 5.2.2. By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Oxytocin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Distribution Channels
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Oxytocin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Distribution Channels
    • 6.3.2. Canada Oxytocin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Distribution Channels
    • 6.3.3. Mexico Oxytocin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Distribution Channels

7. Europe Oxytocin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Distribution Channels
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Oxytocin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Distribution Channels
    • 7.3.2. France Oxytocin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Distribution Channels
    • 7.3.3. United Kingdom Oxytocin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Distribution Channels
    • 7.3.4. Italy Oxytocin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Distribution Channels
    • 7.3.5. Spain Oxytocin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Distribution Channels

8. Asia Pacific Oxytocin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Distribution Channels
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Oxytocin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Distribution Channels
    • 8.3.2. India Oxytocin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Distribution Channels
    • 8.3.3. Japan Oxytocin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Distribution Channels
    • 8.3.4. South Korea Oxytocin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Distribution Channels
    • 8.3.5. Australia Oxytocin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Distribution Channels

9. Middle East & Africa Oxytocin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Distribution Channels
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Oxytocin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Distribution Channels
    • 9.3.2. UAE Oxytocin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Distribution Channels
    • 9.3.3. South Africa Oxytocin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Distribution Channels

10. South America Oxytocin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Distribution Channels
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Oxytocin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Distribution Channels
    • 10.3.2. Colombia Oxytocin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Distribution Channels
    • 10.3.3. Argentina Oxytocin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Distribution Channels

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Oxytocin Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bimeda Group
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. GlaxoSmithKline PLC
  • 15.3. Merck & Co., Inc.
  • 15.4. Grindeks
  • 15.5. Pfizer, Inc.
  • 15.6. Weefsel Pharma
  • 15.7. EVER Pharma
  • 15.8. AdvaCare Pharma
  • 15.9. Fresenius Kabi AG

16. Strategic Recommendations

17. About Us & Disclaimer